Acetic acid derivatives reduce the risk of acute coronary syndrome in patients with diabetes mellitus

2021 ◽  
Author(s):  
Chen-Sheng Chen ◽  
Ming-Yi Shen
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Acetic Acid ◽  
Coronary Syndrome ◽  
Patients With Diabetes

Physical Activity Frequency on the 10-Year Acute Coronary Syndrome (ACS) Prognosis; The Interaction With Cardiovascular Disease History and Diabetes Mellitus: The GREECS Observational Study

2016 ◽  
Vol 24 (4) ◽  
pp. 624-632 ◽  
Author(s):  
Evangelos Papataxiarchis ◽  
Demosthenes B. Panagiotakos ◽  
Venetia Notara ◽  
Matina Kouvari ◽  
Yannis Kogias ◽  
...  
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Protective Effect ◽  
Protective Factor ◽  
Monthly Basis ◽  
Coronary Syndrome ◽  
Activity Frequency ◽  
Patients With Diabetes ◽  
Greek Hospitals

The association between physical activity, diabetes mellitus (DM), and long-term acute coronary syndrome (ACS) prognosis was evaluated. The GREECS study included 2,172 consecutive ACS patients from six Greek hospitals (2003–2004). In 2013–2014, a 10-year follow up was performed with 1,918 patients. Physical activity was categorized in never, rarely (monthly basis), 1–2 and ≥ 3 times/week. Multi-adjusted analysis revealed that 1–2 and ≥ 3 times/week vs. no physical activity had a protective effect on ACS incidence (OR = 0.63 95% CI 0.38, 1.05) and (OR = 0.63 95% CI 0.40, 0.99) respectively, only in patients without prior baseline CVD event. In a subgroup analysis, with DM as strata in these patients, engagement in physical activity (i.e., 1–2 times/week) had a significant protective effect among patients with diabetes (OR = 0.51, 95% CI 0.27, 0.96, p = .037). These findings revealed the beneficial role of exercise in secondary ACS prevention, even in DM patients. Public health-oriented policies should incorporate regular physical activity as a key protective factor in disease prognosis.

Acute coronary syndrome in patients with diabetes mellitus: unified data of multicenter observational trials ORACLE I and ORACLE II

Therapy ◽  
2019 ◽  
Vol 1_2019 ◽  
pp. 68-81 ◽  
Author(s):  
Minushkina L.O. Minushkina ◽  
Brazhnik V.A. Brazhnik ◽  
Averkova A.O. Averkova ◽  
Rogozhina A.A. Rogozhina ◽  
Evdokimova M.A. Evdokimova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Patients With Diabetes

Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome

2018 ◽  
Vol 27 (12) ◽  
pp. 1361-1370 ◽  
Author(s):  
Julia Spoendlin ◽  
Joshua J. Gagne ◽  
Jennifer J. Lewey ◽  
Elisabetta Patorno ◽  
Sebastian Schneeweiss ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Comparative Effectiveness ◽  
Antiplatelet Drugs ◽  
Coronary Syndrome ◽  
Patients With Diabetes

Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome

2014 ◽  
Vol 111 (02) ◽  
pp. 273-278 ◽  
Author(s):  
Marc Laine ◽  
Corinne Frere ◽  
Richard Toesca ◽  
Julie Berbis ◽  
Pierre Barnay ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Platelet Reactivity ◽  
Statistical Significance ◽  
Randomised Trial ◽  
Diabetic Patients ◽  
Loading Dose ◽  
Open Label ◽  
Coronary Syndrome ◽  
Patients With Diabetes

SummaryOptimal P2Y12 receptor blockade is critical to prevent ischaemic recurrence in patients undergoing percutaneous coronary intervention (PCI). We aimed to compare the level of platelet reactivity (PR) inhibition achieved by prasugrel and ticagrelor loading dose (LD) in diabetic acute coronary syndrome (ACS) patients undergoing PCI. We performed a single-center prospective open-label randomised trial. Patients with diabetes mellitus undergoing PCI for an ACS were randomised to receive prasugrel 60 mg or ticagrelor 180 mg. The primary endpoint of the study was the level of platelet reactivity (PR) assessed between 6 and 18 hours post-LD using the VASP index. We randomised 100 diabetic patients undergoing PCI for an ACS. No difference was observed in baseline characteristics between the two groups. In particular, the rate of patient receiving insulin therapy was identical (25 vs 28.6%; p =0.7). Ticagrelor achieved a significantly lower PR compared to prasugrel loading dose (17.3 ± 14.2 vs 27.7 ± 23.3%; p=0.009). In addition the rate of high on-treatment platelet reactivity, defined by a VASP ≥50%, tend to be lower in the ticagrelor group although the difference did not reach statistical significance (6 vs 16%; p=0.2). The rate of low on treatment PR was identical (60 vs 54%; p=0.8). The present study demonstrates that ticagrelor LD is superior to prasugrel LD to reduce PR in ACS patients with diabetes mellitus. Whether the higher potency of ticagrelor could translate into a clinical benefit should be investigated.

scholarly journals 1077-72 Assessment of glycemic control in patients with diabetes mellitus admitted with an acute coronary syndrome

2004 ◽  
Vol 43 (5) ◽  
pp. A406
Author(s):  
Darcy Green Conaway ◽  
David M Safley ◽  
Philip G Jones ◽  
Jonathan Enriquez ◽  
Michelle Stephan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Glycemic Control ◽  
Coronary Syndrome ◽  
Patients With Diabetes

scholarly journals Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy

2012 ◽  
Vol 2012 ◽  
pp. 1-18 ◽  
Author(s):  
Karthik Balasubramaniam ◽  
Girish N. Viswanathan ◽  
Sally M. Marshall ◽  
Azfar G. Zaman
Keyword(s):  
Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Platelet Inhibition ◽  
Cardiovascular Complications ◽  
Diabetic Patients ◽  
Coronary Syndrome ◽  
Patients With Diabetes ◽  
Thrombotic Complications ◽  
Underlying Pathophysiology ◽  
Ischemic Events

Patients with diabetes mellitus presenting with acute coronary syndrome have a higher risk of cardiovascular complications and recurrent ischemic events when compared to nondiabetic counterparts. Different mechanisms including endothelial dysfunction, platelet hyperactivity, and abnormalities in coagulation and fibrinolysis have been implicated for this increased atherothrombotic risk. Platelets play an important role in atherogenesis and its thrombotic complications in diabetic patients with acute coronary syndrome. Hence, potent platelet inhibition is of paramount importance in order to optimise outcomes of diabetic patients with acute coronary syndrome. The aim of this paper is to provide an overview of the increased thrombotic burden in diabetes and acute coronary syndrome, the underlying pathophysiology focussing on endothelial and platelet abnormalities, currently available antiplatelet therapies, their benefits and limitations in diabetic patients, and to describe potential future therapeutic strategies to overcome these limitations.

Sign in / Sign up

Export Citation Format

Share Document